Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Information Provisioning on Solo Channels Is Duty of Both Makers and Wholesalers: JPMA Distribution Chief
Amid growing scrutiny of single-wholesaler distribution under Japan’s revised drug distribution guidelines, Japan Pharmaceutical Manufacturers Association (JPMA) Distribution Improvement Committee Chair Yusuke Kumagai emphasized that both drug makers and wholesalers bear responsibility for providing information and ensuring stable supplies, regardless…
To read the full story
Related Article
- JPMA Think Tank Chief Pledges to Back Policy Debates with Evidence
September 26, 2025
- JPMA to Overhaul Guideline for Handling Drug Inquiries This Fall: Consultation Chair
September 25, 2025
- JPMA Publishes TPP Overview to Bridge Academia and Industry: R&D Chair
September 22, 2025
- JPMA Sets Up Multilateral Advocacy Group to Bolster Global Voice: International Affairs Chair
September 19, 2025
- JPMA Launches Task Force on AI and Open Innovation Challenges: IP Chief
September 18, 2025
- JPMA to Broaden Base of Biopharma Talent through On-Site Training: Committee Chair
September 17, 2025
- JPMA to Compile Best Practices on Patient and Public Involvement
September 16, 2025
- JPMA Plans Joint Training with HCPs to Improve Promo Materials: Review Board Chair
September 11, 2025
- JPMA to Step Up Public Outreach, Build Understanding of Pharma, Says PR Head
September 10, 2025
- JPMA Quality Committee Launches Task Force on DX in Commercial Production
September 9, 2025
- JPMA Code & Compliance Chair Stresses Need to Embed Spirit of Revised COP
September 8, 2025
- JPMA ICH Project Chair Sees RWE as Potential Complement to Clinical Trials
September 5, 2025
- Rules for Measuring Industry-Wide Emissions in the Works: JPMA Environment Chief
September 4, 2025
- JPMA Regulatory Chief Seeks Balanced Approach on Japanese PI Waivers
September 3, 2025
- Clinical Trial Environment Must Match Global Standards, Says JPMA Evaluation Chief
September 2, 2025
- Indicators Needed to Frame Pharma as Growth Market in Japan, Says JPMA Policy Chief
August 29, 2025
ORGANIZATION
- Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
- Japan’s Contract Rep Workforce Hits Record High in FY2025
July 6, 2026
- Japan’s Generic Use Rate Climbs to 89.7% in FY2025: JGA
July 6, 2026
- FPMAJ Sets Up Drug Security Task Force under Chairman
July 3, 2026
- JETRO Opens 2026 Applications for Regenerative Medicine Program
July 2, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…